Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Payers' Guide
Select Drug Profiles
,
Payers' Guide
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Kevzara (Sarilumab), a New IL-6 Receptor Antagonist, Approved for Active Rheumatoid Arthritis
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Nerlynx (Neratinib) First Extended Adjuvant Therapy Approved for HER2-Positive Breast Cancer
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Shingrix (Zoster Vaccine Recombinant) a New Vaccine Approved for Herpes Zoster Prevention in Older Adults
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Simponi Aria (Golimumab), the Only Fully Human Anti–TNF-α Infused Therapy, Now Approved for Active Psoriatic Arthritis and for Active Ankylosing Spondylitis
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
Read More
1
2
3
4
5
6
7
Page 4 of 19
Results 31 - 40 of 185